Last reviewed · How we verify
keflex
At a glance
| Generic name | keflex |
|---|---|
| Also known as | cephalexin |
| Sponsor | University of Pennsylvania |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Comparative Randomized, Single Dose, Two-way Crossover, Open-label Study to Determine the Bioequivalence of Cefadroxil From Duricef 1 gm Film Coated Tablets (Smithkline Beecham Egypt, LLC Affiliated C (Phase 4)
- Antibiotic Treatment for Intermittent Bladder Catheterisation: A Randomised Controlled Trial of Once Daily Prophylaxis (Phase 4)
- Oral vs Intravenous Antibiotics for Treatment of Periprosthetic Joint Infection (Phase 3)
- Antibiotics After Breast Reduction:Clinical Trial With Randomization (Phase 2)
- The Effect of Losartan on Cephalexin (Phase 1)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (Phase 4)
- A RCT in Sweden of Acupuncture and Care Interventions for the Relief of Inflammatory Symptoms of the Breast During Lactation (NA)
- The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- keflex CI brief — competitive landscape report
- keflex updates RSS · CI watch RSS
- University of Pennsylvania portfolio CI